Pancreatic cancer–the past, the present, and the future
(2022) In Scandinavian Journal of Gastroenterology 57(10). p.1169-1177- Abstract
Background: Pancreatic cancer has been and still is associated with a very poor prognosis. This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication, prediction, as well as novel, targeted therapies. The benefits of surgery and chemotherapy are evident, but the fact that only some 10% of all patients have early, localized disease highlights the unmet need for new early detection methods. An improved understanding of tumor biology and the development of molecular markers detectable both in the circulation and in cancer tissues may underlie the development of new tools for optimizing both diagnosis and treatment. Material and methods: Review of the literature. Results and conclusion: If we do not... (More)
Background: Pancreatic cancer has been and still is associated with a very poor prognosis. This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication, prediction, as well as novel, targeted therapies. The benefits of surgery and chemotherapy are evident, but the fact that only some 10% of all patients have early, localized disease highlights the unmet need for new early detection methods. An improved understanding of tumor biology and the development of molecular markers detectable both in the circulation and in cancer tissues may underlie the development of new tools for optimizing both diagnosis and treatment. Material and methods: Review of the literature. Results and conclusion: If we do not improve precision oncology for pancreatic ductal adenocarcinoma, the prognosis will still remain dismal and the” burden” on society will increase substantially.
(Less)
- author
- Andersson, Roland LU ; Haglund, Caj ; Seppänen, Hanna and Ansari, Daniel LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- diagnosis, oncology, Pancreatic ductal adenocarcinoma, precision, prognosis
- in
- Scandinavian Journal of Gastroenterology
- volume
- 57
- issue
- 10
- pages
- 1169 - 1177
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85129848984
- pmid:35477331
- ISSN
- 0036-5521
- DOI
- 10.1080/00365521.2022.2067786
- language
- English
- LU publication?
- yes
- id
- 25127e60-f5cf-46ce-9ca0-be56864f85b0
- date added to LUP
- 2022-07-14 12:56:41
- date last changed
- 2024-04-18 09:31:05
@article{25127e60-f5cf-46ce-9ca0-be56864f85b0,
abstract = {{<p>Background: Pancreatic cancer has been and still is associated with a very poor prognosis. This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication, prediction, as well as novel, targeted therapies. The benefits of surgery and chemotherapy are evident, but the fact that only some 10% of all patients have early, localized disease highlights the unmet need for new early detection methods. An improved understanding of tumor biology and the development of molecular markers detectable both in the circulation and in cancer tissues may underlie the development of new tools for optimizing both diagnosis and treatment. Material and methods: Review of the literature. Results and conclusion: If we do not improve precision oncology for pancreatic ductal adenocarcinoma, the prognosis will still remain dismal and the” burden” on society will increase substantially.</p>}},
author = {{Andersson, Roland and Haglund, Caj and Seppänen, Hanna and Ansari, Daniel}},
issn = {{0036-5521}},
keywords = {{diagnosis; oncology; Pancreatic ductal adenocarcinoma; precision; prognosis}},
language = {{eng}},
number = {{10}},
pages = {{1169--1177}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Gastroenterology}},
title = {{Pancreatic cancer–the past, the present, and the future}},
url = {{http://dx.doi.org/10.1080/00365521.2022.2067786}},
doi = {{10.1080/00365521.2022.2067786}},
volume = {{57}},
year = {{2022}},
}